Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04358107 · ClinicalTrials.gov registry record
Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
A clinical trial of Adrenocortical Carcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT04358107 is a study of Adrenocortical Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 1,000 participants, above the 239-participant average among 8 other Adrenocortical Carcinoma trials with a reported enrollment target (318% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04358107, a study of Adrenocortical Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Adrenocortical carcinoma (ACC) is a rare cancer. It has a poor prognosis. Some people live with ACC for years; others live for just months. The average survival from the time of diagnosis is 14.5 months. Researchers do not know if local directed treatments may work better than systemic ones. They want to learn more about ACC by looking at data from previous studies. Objective: To characterize the overall prognosis and treatment responses in people with ACC with various systemic therapies and correlate them with age, sex, race, and disease burden. Eligibility: People with ACC enrolled on any of the following studies: 92-C-0268, 93-C-0200, 00-C-0044, 01-C-0129, 04-C-0011, 09-C-0242, 08-C-0176, 10-C-0203, 13-C-0114, and 14-C-0029 Design: Study researchers will review participants medical records. They will collect the following data: Medical record numbers Demographics (such as age, sex, and race) Treatments (such as surgeries, radiology procedures, and systemic treatments) Time of disease progression between treatments and genetic/molecular data (if available) Time of diagnosis/time of death. All data will be kept in secure network drives or sites. Participants who opted out of future use of data on their prior studies will be not be included in this study.
Conditions Studied
Study Locations (1)
Maryland
- National Cancer Institute (NCI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2020-04-20 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04358107
The ClinicalTrials.gov registry entry for NCT04358107 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 239-participant average among 8 other Adrenocortical Carcinoma trials with a reported enrollment target (318% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adrenocortical Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT04358107 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04358107 about?
NCT04358107 is a clinical study titled "Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)". Background: Adrenocortical carcinoma (ACC) is a rare cancer. It has a poor prognosis. Some people live with ACC for years; others live for just months. The average survival from the time of diagnosis is 14.5 months. Researchers do not know if local directed treatments may work better than systemic ...
What is the current status of trial NCT04358107?
This trial is currently active not recruiting. The enrollment target is 1,000 participants. The study started on 2020-04-20. Estimated completion is 2026-12-31.
What conditions does trial NCT04358107 study?
This clinical trial studies the following conditions: Adrenocortical Carcinoma.
Who is sponsoring clinical trial NCT04358107?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04358107 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adrenocortical Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
RECRUITING · Phase 2
-
Familial Investigations of Childhood Cancer Predisposition
RECRUITING
-
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
RECRUITING · Phase 2
-
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.